重磅信号！国家药监局“拍板定调”，脑机接口产业迎来“国家队”加速，5大核心赛道或将引爆！

Core Insights - The National Medical Products Administration (NMPA) held a meeting on December 18 to discuss the advancement of brain-computer interface (BCI) medical devices, emphasizing the strategic importance of BCI in future industries [1][2] Industry Analysis - Medical Devices and Rehabilitation Equipment: BCI technology is being implemented in the medical rehabilitation sector, with multiple companies entering clinical trial phases, indicating significant market potential [3] - Artificial Intelligence and Big Data: BCI relies on high-precision algorithms and large data processing, leading AI companies to invest in areas such as EEG signal decoding and emotion recognition, driving technological advancements [3] - Consumer Electronics and Smart Wearables: Non-invasive BCIs are rapidly being adopted in gaming, education, and fatigue monitoring, with smart wearable manufacturers launching brain-controlled products, expanding market opportunities [3] - Semiconductors and Sensors: Key hardware components like high-channel electrodes and flexible sensors are critical to the BCI supply chain, with technological breakthroughs directly impacting system performance and costs [3] Company Overview - Innovative Medical (002173.SZ): Holds a 40% stake in Boling Medical and leads the only invasive BCI system (BCI-4000) in China currently in Phase III clinical trials, comparable to Neuralink [4] - Hanwei Technology (300007.SZ): Its subsidiary, Suzhou Nengsida, is developing flexible tactile sensors for BCI devices and is expected to win a key project from the Ministry of Industry and Information Technology by 2025 [4] - iFlytek (002230.SZ): Leverages AI technology to establish a collaborative laboratory with South China University of Technology, achieving a 92% accuracy rate in EEG emotion recognition systems [4] - Sanbo Neuroscience (301293.SZ): A leader in neurology, collaborating with Tsinghua University to establish a clinical transformation center for BCI, with its wireless minimally invasive device NEO entering Phase III clinical trials [4] - Yanshan Technology (002195.SZ): Engages in both AI computing and BCI, with breakthroughs in neural signal decoding and applications in early screening for cognitive disorders [4] - Chengyitong (300430.SZ): A leading player in the BCI sector, focusing on neuroregulation and rehabilitation devices, with products currently in trial at various hospitals [5]